Tag: LAA

FEops HEARTguide Proven to Significantly Enhance Efficiency and Outcomes of LAA Closure Procedures

GENT, Belgium–(BUSINESS WIRE)–Today, FEops announced the publication of the PREDICT-LAA study in JACC: Cardiovascular Interventions, showing that Left Atrial Appendage Closure (LAAC) procedures planned by means of FEops HEARTguide™ resulted in significant improvement of procedural efficiency and outcomes. Prof. Dr. […]

FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US

SHENZHEN, China, Sept. 5, 2022 /PRNewswire/ — LifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance […]

ABBOTT RECEIVES EUROPEAN AND CANADIAN APPROVAL FOR AMPLATZER™ STEERABLE DELIVERY SHEATH TO OPTIMIZE LEFT ATRIAL APPENDAGE CLOSURE PROCEDURES FOR PEOPLE AT RISK OF STROKE

– First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation – New delivery system works with Abbott’s leading Amplatzer Amulet™ LAA […]

LifeTech announced the launch of its global post-market surveillance study for LAmbre (TM) LAA Closure System

NEWS PROVIDED BY LifeTech Scientific Corporation 03 Jul, 2017, 11:56 BST FRANKFURT, Germany, July 3, 2017 /PRNewswire/ — On June 30, at the Congenital and Structural Intervention Congress (CSI) 2017 in Frankfurt, LifeTech Scientific Corporation (Stock Code: 1302.HK) announced the launch of a 3-year global post-market […]